32.21MMarket Cap-3085P/E (TTM)
3.6500High3.5300Low4.41KVolume3.5300Open3.6200Pre Close15.87KTurnover0.07%Turnover RatioLossP/E (Static)8.92MShares6.799952wk High3.32P/B24.41MFloat Cap2.400052wk Low--Dividend TTM6.76MShs Float2447.9980Historical High--Div YieldTTM3.32%Amplitude0.6700Historical Low3.6010Avg Price1Lot Size
Marker Therapeutics Stock Forum
Marker Therapeutics Awarded $2 Million Grant From Nih in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients With Non-Hodgkin’s Lymphoma
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nation...
$Atlantica Sustainable Infrastructure (AY.US)$ $Vinco Ventures (BBIG.US)$ $Becton Dickinson & Co (BDX.US)$ $Bluejay Diagnostics (BJDX.US)$ $F5 Inc (FFIV.US)$ $Hexcel (HXL.US)$ $Intuitive Surgical (ISRG.US)$ $Kodiak Sciences (KOD.US)$ $Koss Corp (KOSS.US)$ $Marker Therapeutics (MRKR.US)$ $NeuroOne Medical (NMTC.US)$ $NXP Semiconductors (NXPI.US)$ $RLI Corp (RLI.US)$ $Tupperware Brands (TUP.US)$ $Whirlpool (WHR.US)$ $Expion360 (XPON.US)$
No comment yet